GlassScriptPhysician profile
Gregory Todd Pleasants
NPI 1144282435
$4,007.57
in general payments reported to CMS, 2019-2025
32 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $47.68 · 2021: $339 · 2022: $920 · 2023: $695 · 2024: $1,007 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Preventric Diagnostics, INC. | $647.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.41 | 2020-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $230.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $192.87 | 2019-2025 | |
| Abbott Laboratories | $169.32 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $150.41 | 2020-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $149.01 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $144.06 | 2019-2024 | |
| Bausch Health US, LLC | $107.56 | 2022-2025 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $97.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $97.06 | 2019-2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $96.51 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $94.08 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $89.55 | 2023-2024 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72.88 | 2019-2021 | |
| Gilead Sciences, INC. | $69.96 | 2021-2025 | |
| Medtronic, INC. | $59.70 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $59.11 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.19 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $45.66 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $37.56 | 2019-2022 | |
| Astellas Pharma US INC | $31.19 | 2023-2024 | Veozah, Myrbetriq |
| Rhythm Pharmaceuticals, INC. | $25.33 | 2023 | Imcivree |
| Eisai INC. | $17.13 | 2024 | |
| Axsome Therapeutics, INC. | $16.61 | 2025 | Auvelity |
| Sonex Health, INC. | $16.02 | 2024 | Sx-One Microknife |
| Dexcom, INC. | $15.71 | 2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $15.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.94 | 2021 | |
| Genentech USA, INC. | $12.32 | 2019 | |
| Amarin Pharma, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pleasants listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.